|Day Low/High||23.14 / 24.23|
|52 Wk Low/High||21.22 / 42.00|
Regardless of what is moving the markets, it is a good example of how you have to focus on price action above all else.
The stock's decline with the sector has occurred despite a steady supply of positive news.
There are obvious signs that people are trying to put cash to work.
After two chaotic days, Wall Street is trading relatively calmly, creating opportunities for individual names to show life.
As long as the indices remain under pressure there is no benefit to picking stocks.
My overall market view right now is to maintain a bullish bias but look for some pullbacks to support.
I find it difficult to believe that there won't be something positive out of the G-20 meeting.
The problem KSS faces is that reports from retailers are being automatically sold in this poor market right now.
It's weeks like this that I'm glad I have some 'dry powder' to deploy.
Let's check out the charts and indicators.
There is no question that we are becoming extended and ripe for some profit taking.
Whether this market continues to bounce is going to depend a great degree on the FAANG names.
Many stocks are already at support levels and are offering opportunities to start some positions.
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
This market may be extended by just about any measure, but that doesn't mean you should be fighting it.
Breadth is slightly negative as markets ease into 3-day weekend.
The applications for this distributed ledger technology are endless.
The republican loss in the Alabama special election for U.S. senate had only a brief imapct on stock futures.
Small-caps are lagging and breadth is negative, but the computer algorithms are very impressive.
The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.